Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Drugs industry as a whole closed the day up 0.9% versus the S&P 500, which was unchanged. Laggards within the Drugs industry included ImmuCell ( ICCC), down 3.8%, China Pharma ( CPHI), down 1.8%, Heat Biologics ( HTBX), down 2.4%, Chembio Diagnostics ( CEMI), down 1.9% and Merus Labs International ( MSLI), down 2.6%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Chembio Diagnostics ( CEMI) is one of the companies that pushed the Drugs industry lower today. Chembio Diagnostics was down $0.06 (1.9%) to $3.36 on average volume. Throughout the day, 21,653 shares of Chembio Diagnostics exchanged hands as compared to its average daily volume of 19,300 shares. The stock ranged in price between $3.35-$3.44 after having opened the day at $3.43 as compared to the previous trading day's close of $3.42.

Chembio Diagnostics has a market cap of $33.0 million and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Friday. Currently there are 3 analysts who rate Chembio Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Heat Biologics ( HTBX) was down $0.10 (2.4%) to $4.03 on heavy volume. Throughout the day, 30,314 shares of Heat Biologics exchanged hands as compared to its average daily volume of 12,700 shares. The stock ranged in price between $4.01-$4.21 after having opened the day at $4.03 as compared to the previous trading day's close of $4.13.

Heat Biologics has a market cap of $26.8 million and is part of the health care sector. Shares are down 41.8% year-to-date as of the close of trading on Friday. Currently there is 1 analyst who rates Heat Biologics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on HTBX go as follows:

You can view the full analysis from the report here: Heat Biologics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

China Pharma ( CPHI) was another company that pushed the Drugs industry lower today. China Pharma was down $0.01 (1.8%) to $0.33 on light volume. Throughout the day, 10,530 shares of China Pharma exchanged hands as compared to its average daily volume of 100,000 shares. The stock ranged in price between $0.32-$0.34 after having opened the day at $0.34 as compared to the previous trading day's close of $0.34.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $14.6 million and is part of the health care sector. Shares are down 2.6% year-to-date as of the close of trading on Friday.

TheStreet Ratings rates China Pharma as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • CHINA PHARMA HOLDINGS INC has improved earnings per share by 16.7% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, CHINA PHARMA HOLDINGS INC swung to a loss, reporting -$0.45 versus $0.10 in the prior year.
  • CPHI, with its decline in revenue, slightly underperformed the industry average of 6.3%. Since the same quarter one year prior, revenues fell by 14.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • 41.65% is the gross profit margin for CHINA PHARMA HOLDINGS INC which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -33.63% is in-line with the industry average.
  • Net operating cash flow has significantly increased by 124.81% to $2.49 million when compared to the same quarter last year. In addition, CHINA PHARMA HOLDINGS INC has also vastly surpassed the industry average cash flow growth rate of -54.80%.

You can view the full analysis from the report here: China Pharma Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.